STOCK TITAN

Xencor to Present at the SVB Securities Global Biopharma Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, will present at the virtual 2023 SVB Securities Global Biopharma Conference on February 14, 2023, at 3:40 p.m. ET. The presentation will focus on the company's innovative engineered antibodies and cytokines aimed at treating cancer and autoimmune diseases. A live webcast will be available in the Investors section of Xencor's website, with an archived replay accessible for at least 30 days following the event. Xencor is advancing over 20 clinical candidates developed with its XmAb® technology.

Positive
  • None.
Negative
  • None.

MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the virtual 2023 SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 3:40 p.m. ET / 12:40 p.m. PT.

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. After the webcast, a replay will be archived on the website for at least 30 days.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Charles Liles

cliles@xencor.com

626-737-8118

Source: Xencor, Inc.

FAQ

When will Xencor present at the SVB Securities Global Biopharma Conference?

Xencor will present at the virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 3:40 p.m. ET.

Where can I watch Xencor's presentation from the conference?

Xencor's presentation will be available via a live webcast in the Investors section of their website.

What is Xencor developing?

Xencor is developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases.

How many candidates is Xencor currently developing?

Xencor has more than 20 clinical candidates in development utilizing its XmAb® technology.

What is XmAb® technology?

XmAb® technology involves small modifications to a protein's structure to create new therapeutic action mechanisms.

Xencor, Inc.

NASDAQ:XNCR

XNCR Rankings

XNCR Latest News

XNCR Stock Data

1.71B
68.81M
0.89%
104.54%
5.86%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PASADENA